Novavax Research President 'Optimistic' About A Coronavirus Vaccine In January

This week, U.S. drugmaker Novavax said it's ready to start a new midstage trial of its experimental COVID-19 vaccine in South Africa. The Maryland company has said it's on track to begin final-stage trials as soon as late September.

Last month, the Trump administration awarded Novavax a $1.6 billion contract as part of its Operation Warp Speed program, which aims to deliver 300 million doses of a vaccine against the coronavirus by January.

Here & Now's Tonya Mosley speaks with Dr. Gregory Glenn, president of research and development at Novavax and head of the company's vaccines programs.